MX2007004596A - Nitrobenzoindoles y su uso en terapia del cancer. - Google Patents

Nitrobenzoindoles y su uso en terapia del cancer.

Info

Publication number
MX2007004596A
MX2007004596A MX2007004596A MX2007004596A MX2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A
Authority
MX
Mexico
Prior art keywords
cancer therapy
nitrobenzindoles
drugs
radiosensitizers
indoles
Prior art date
Application number
MX2007004596A
Other languages
English (en)
Inventor
William Alexander Denny
William Robert Wilson
Shangjin Yang
Ralph James Stevenson
Moana Tercel
Graham John Atwell
Adam Vorn Patterson
Frederik Bastiaan Pruijn
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of MX2007004596A publication Critical patent/MX2007004596A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion se refiere generalmente a nitro-1,2-dihidro-3H-benzo[e]indoles y analogos relacionados, a su preparacion, y a su uso como farmacos selectivos de hipoxia y radiosensibilizadores para terapia de cancer, ambos juntos o en combinacion con radiacion y/u otros farmacos anticancerigenos.
MX2007004596A 2004-10-22 2005-10-21 Nitrobenzoindoles y su uso en terapia del cancer. MX2007004596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ536107A NZ536107A (en) 2004-10-22 2004-10-22 Nitrobenzindoles and their use in cancer therapy
PCT/NZ2005/000278 WO2006043839A1 (en) 2004-10-22 2005-10-21 Nitrobenzindoles and their use in cancer therapy

Publications (1)

Publication Number Publication Date
MX2007004596A true MX2007004596A (es) 2007-06-22

Family

ID=36203204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004596A MX2007004596A (es) 2004-10-22 2005-10-21 Nitrobenzoindoles y su uso en terapia del cancer.

Country Status (14)

Country Link
US (1) US7718688B2 (es)
EP (1) EP1809603A4 (es)
JP (1) JP2008517905A (es)
KR (1) KR20070083806A (es)
CN (1) CN101044114B (es)
AU (1) AU2005296389B2 (es)
BR (1) BRPI0517285A (es)
CA (1) CA2584702A1 (es)
IL (1) IL182652A0 (es)
MX (1) MX2007004596A (es)
NZ (1) NZ536107A (es)
RU (1) RU2007118938A (es)
WO (1) WO2006043839A1 (es)
ZA (1) ZA200703699B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009956A (es) * 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8076491B2 (en) 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
CA2696995C (en) 2007-08-21 2017-11-21 Senomyx, Inc. Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
NZ571028A (en) * 2008-09-03 2011-01-28 Auckland Uniservices Ltd Nitrobenzindole compounds and their use in cancer treatment
PL2344478T3 (pl) 2008-11-03 2018-02-28 Syntarga B.V. Analogi CC-1065 oraz ich koniugaty
LT2560645T (lt) * 2010-04-21 2016-10-10 Syntarga B.V. Cc-1065 analogų ir bifunkcinių linkerių konjugatai
CN102827061A (zh) * 2012-09-19 2012-12-19 兰州大学 5,6,7-三甲氧基吲哚类衍生物、制备方法及用途
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
RU2769700C2 (ru) 2014-01-10 2022-04-05 Байондис Б.В. Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
KR20160099725A (ko) 2014-01-10 2016-08-22 신톤 바이오파머슈티칼즈 비.브이. 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
KR102323301B1 (ko) 2014-01-10 2021-11-09 비온디스 비.브이. Cys 연결된 항체-약물 접합체의 정제 방법
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
JPWO2019004413A1 (ja) * 2017-06-30 2020-05-07 東レ株式会社 インドリン誘導体及びそれを含む細胞毒性剤
CN112724068A (zh) * 2020-12-30 2021-04-30 蔡桂坡 具有hdac抑制活性的吲哚类衍生物的合成方法及肿瘤应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334344A (en) * 1996-09-12 2000-08-25 Cancer Res Campaign Tech benzo[e]indole and pyrrolo[3,2-e]indole compounds and their use as prodrugs
US7192977B2 (en) * 2001-02-22 2007-03-20 School Of Pharmacy Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
AU2003228173A1 (en) 2002-05-17 2003-12-02 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-(ring fused indol-5-yl(amine-derived)) compounds and analogues thereof, and to products obtained therefrom
NZ529249A (en) 2003-10-31 2006-04-28 Auckland Uniservices Ltd Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic

Also Published As

Publication number Publication date
CA2584702A1 (en) 2006-04-27
US20080119442A1 (en) 2008-05-22
JP2008517905A (ja) 2008-05-29
BRPI0517285A (pt) 2008-10-07
RU2007118938A (ru) 2008-11-27
IL182652A0 (en) 2007-07-24
ZA200703699B (en) 2008-10-29
CN101044114A (zh) 2007-09-26
US7718688B2 (en) 2010-05-18
WO2006043839A1 (en) 2006-04-27
AU2005296389A1 (en) 2006-04-27
EP1809603A4 (en) 2009-09-02
AU2005296389B2 (en) 2012-03-15
EP1809603A1 (en) 2007-07-25
KR20070083806A (ko) 2007-08-24
NZ536107A (en) 2007-06-29
CN101044114B (zh) 2012-02-15

Similar Documents

Publication Publication Date Title
MX2007004596A (es) Nitrobenzoindoles y su uso en terapia del cancer.
TW200600091A (en) Sulfonylethyl phosphorodiamidates
IL186230A0 (en) Anticancer combination therapy using sunitinib malate
WO2001012199A3 (en) Methoxyamine potentiation of temozolomide anti-cancer activity
WO2010110685A3 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2007033023A3 (en) Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
ZA200805163B (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
HK1123282A1 (en) Oxygen linked pyrimidine derivatives
EP2056818A4 (en) COMPOSITIONS AND METHODS FOR NEUROPROTECTION
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
WO2005067980A3 (en) Design of therapeutics and therapeutics
EP1713474A4 (en) INDIRUBINE DERIVATIVES WITH ANTICANCER PROPERTIES AGAINST CANCER CELLS IN HUMANS
WO2008089397A3 (en) Adrb2 cancer markers
EP2004637A1 (en) Substituted ring fused azines and their use in cancer therapy
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2011054837A3 (de) Bifunktionale prodrugs und drugs
WO2007019308A3 (en) Illudin analogs useful as anticancer agents
WO2005076888A3 (en) Anti-cancer therapies
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
ZA200701578B (en) Combination anticancer therapy and pharmaceutical compositions therefore
WO2011056566A3 (en) Compounds and methods for treatment of cancer
ZA200708873B (en) Anticancer combination therapy using sunitinib malate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal